Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


15 Items
Title  Creator  Group name  Publishing year 
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer Vendrell et al. EquipeCTCS 2023-09-16
PeroxiHUB: A Modular Cell-Free Biosensing Platform Using H2O2 as Signal Integrator Soudier et al. EquipePC 2022-08-19
ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets Cabello-Aguilar et al. EquipePC 2022-12-13
Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota Vendrell et al. EquipePC 2022-01-25
Case report: Liquid biopsy, the sooner the better? Thomas et al. EquipePC 2022
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome Vendrell et al. EquipePC 2021-11
TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma Blateau et al. EquipePC Aug 09, 2020
Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment Vendrell et al. EquipePC 2020
Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs Vendrell et al. EquipeMY 2019-07-15
Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer Vendrell et al. EquipePC 2018
Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer Solassol et al. EquipePC 08 28, 2018
Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection Vendrell et al. EquipePC 11 2018
High-throughput detection of clinically targetable alterations using next-generation sequencing Vendrell et al. EquipePC Jun 20, 2017
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches Vendrell et al. EquipePC 10 02, 2017
Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management Vendrell et al. EquipePC Jan 29, 2017
15 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés